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Objectives: to assess the early morbidity and mortality of a new treatment, the endovascular repair of abdominal aortic
aneurysms, during its introduction into clinical practice.
Design: a prospective voluntary registry collecting demographic and risk factor data, details of aneurysm morphology,
procedure performed, immediate and 30-day outcomes.
Setting: thirty-one U.K. centres performing endovascular repair submitted data.
Results: six hundred and eleven cases were registered in 3 years of data collection (January 1996 to December 1998).
Four per cent of patients received an aortic tube device, 60% an aorto-bi-iliac device and 36% an aorto-uni-iliac device
and a crossover graft (AUIC). Conversion to open repair was required in 5% of cases, with more conversions in the
AUIC group (OR 2.9 (95% CI: 1.3–6.4) p=0.01) Post procedure complications occurred in 25% of cases. Unfit patients
had significantly more complications than fit patients (35% vs 20% for fit patients (OR 1.8 (95% CI: 1.2–2.7) p=
0.007)). At 30 days aneurysms were excluded in 90% of cases. Endoleaks were more common in larger aneurysms (2%
if aneurysms were <6 cm in diameter vs 10% if >6 cm, OR 5.6 (95% CI: 2.1–14.9) p=0.0006). The overall mortality
was 7% but was significantly higher for AUIC devices, (4% for combined aortic tube and bi-iliac devices (AT/BI) vs
12%, OR 2.6 (95% CI: 1.2–5.9 p=0.018), and unfit patients (4% for fit patients vs 18%, OR 4.3 (95% CI: 2.0–9.5)
p<0.001).
Conclusions: endovascular repair is feasible with short-term outcomes comparable to those of conventional surgical
repair. In unfit patients the possible benefit in life expectancy gain must to be balanced against the morbidity and mortality
of the procedure.
Introduction severe co-morbid conditions who would therefore be
considered unfit for conventional surgical repair, as
Since it was first described in 1991, the feasibility of well as to fit patients. This raises important ethical
endovascular treatment of abdominal aortic aneurysm and consent issues in unfit patients if conversion to
(AAA) has been firmly established.1–5 In essence, dur- an open repair becomes necessary because of com-
ing endovascular repair the endograft is positioned plications. Not all patients can be treated endo-
within the aorta by a transfemoral or transiliac route vascularly, with aneurysm morphology being the
to exclude the aneurysm sac from the circulation; the major determinant of suitability. At present the pro-
graft being anchored by one or more metallic stents portion of aneurysms suitable for endovascular repair
below the renal arteries. The technique, though cur- are estimated to be between 30–50%, with aorto-uni-
rently requiring an arterial cutdown, avoids the need iliac devices advocated as being usable in a larger
for surgical exposure of the aorta and aortic cross proportion of cases.6
clamping and as such is “minimally invasive”, with Though there has been considerable enthusiasm for
potentially reduced morbidity and mortality. This po- endovascular repair of AAA, there have been concerns
tential has resulted in it being offered to patients with that the technique may be widely introduced prior
to proper evaluation.7 The Registry of Endovascular
Treatment of Abdominal Aortic Aneurysms (RETA)
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of Great Britain and Ireland and the British Society of graft material, the device is constructed for each case,
whereas the AT/BI devices are commercially availableInterventional Radiology.8 Its purpose is to assess the
safety and efficacy of this new and rapidly changing ready-made. The results for these two subgroups (AUI
and crossover group (AUIC), and AT/BI group) havetechnology during its introduction into clinical prac-
tice. We present the short-term (30-day) morbidity and been analysed separately. Because of concerns about
the treatment of “unfit” patients, subgroups of “fit”mortality data from the first 3 years (1 January 1996
to 31 December 1998) of data collection. and “unfit” were analysed separately. Patients cor-
responding to American Society of Anaesthesiology
(ASA) grade IV or V or who were specified as un-
suitable for conventional repair because of co-mor-
Methods bidity were deemed “unfit”; ASA grade I–III were
deemed “fit”. Another subgroup of patients were iden-
Registry details tified as “fit” by ASA grade but “unsuitable” for
conventional open repair because the presence of,
The registry was co-ordinated at the Sheffield Vascular for example, a hostile abdomen or an inflammatory
Institute on behalf of the Joint Working Party of the aneurysm made the open procedure high risk. As
Vascular Surgical Society (VSS) of Great Britain and larger aneurysms may be more difficult to treat, sub-
Ireland and the British Society of Interventional Ra- groups of AAA diameter <6 cm and >6 cm were ana-
diology (BSIR). Data submission was voluntary with lysed separately. This paper focuses on complications
all United Kingdom members of the VSS and BSIR and 30-day outcomes which are presented for the total
asked to submit their cases on a simple registration data set as descriptive statistics. Chi-squared tests of
form. independence (for categorical data) and t-tests (for
The case registration form recorded details of patient continuous data) were used to assess differences in
age, clinical indication for the procedure, co-morbidity baseline data. Logistic regression was used to compare
precluding conventional repair, anaesthetic risk, an- differences in outcomes between groups with ad-
eurysm morphology, device used, procedure details justments made for available confounders (fitness for
(anaesthesia used, length of procedure and blood loss), repair, indication for repair, age, device type, aneurysm
plus immediate and 30-day outcomes and length of diameter) as appropriate. Cox proportional hazard
hospital stay. Immediate outcomes recorded were: an- models were used to assess differences in length of
eurysm exclusion at the end of the procedure; whether in-patient stay, adjusted for confounders of patient
additional endovascular procedures, additional sur- age, indication for repair, fitness and device type.
gical treatments or conversion to an open repair were
required, and whether there was evidence of endoleak
(continued filling of the aneurysm sac) at the end of
Resultsthe procedure. Complications post procedure and their
treatment were recorded. At 30 days the main out-
Between 1 January 1996 and 31 December 1998, 611comes recorded were exclusion of the aneurysm sac,
cases were submitted to the registry from 31 centres.mortality, major amputation, and presence of
A median of 11 cases (range 1–115) were submittedendoleak.
per centre. The number of cases submitted increased
from 146 in 1996, to 183 in 1997 and 282 in 1998.
Basic patient characteristics are shown in Table 1.
The mean (range; S.D.) age of patients was 72 (44–93;Analysis
7.56) years. There was no statistically significant dif-
ference in age between patients treated with an AT/For the purposes of analysis subgroups of patients
were identified. There were two main types of device: BI device and an AUIC device (71 years vs 72 years,
respectively; (mean difference +1.1 years, 95% CI:(i) the aorto-uni-iliac (AUI) devices, which require a
more surgical technique with a crossover graft, but +2.4; −0.2, p=0.08)), nor between fit patients and
unfit patients (71 years vs 71 years, respectively; (meancan be used on a larger proportion of aneurysms;6 and
(ii) the aortic tube or bi-iliac (AT/BI) devices which difference −0.2 years, 95% CI: +1.3; −1.6, p=0.8)).
Patients with smaller aneurysms were significantlyinvolve a more endovascular technique. The AUI de-
vice group contains a large number of “home made” younger than those with aneurysms >6 cm in diameter
(70 years vs 72 years, respectively; (mean differencedevices constructed by using available materials, such
as Palmaz stents and Polytetrafluoroethylene (PTFE) +1.9 years (95% CI: +3.2; −0.4) p=0.002)).
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Table 1. Patient characteristics.
Characteristics All AT/BI AUIC OR (95% CI) p value
Age 72 71 72 Mean 1.1 year 0.08
(+2.4; −0.2)
Unfit patients 131/603 57/387 74/216 3.0 (2.0–4.5) <0.001
(22%) (15%) (34%)
Fit, unsuitable for open repair 36/472 16/330 20/142 3.2 (1.6–6.4) 0.001
(8%) (5%) (14%)
Aneurysm size >6 cm 304/585 170/380 134/205 2.3 (1.6–3.3) <0.001
(52%) (45%) (65%)
AT/B: Aortic tube and bi-iliac devices; AUI: aorto-uni-iliac devices.
Table 2. Endoprosthesis type.Endovascular repairs were performed electively for
asymptomatic aneurysms in 82% (502/608) of cases, Device Number
(%)electively for symptoms in 14% (86/608), acutely for
non-ruptured AAA in 2% (10/608) and for acute rup-
Ancure (Guidant EVT Europe) 36 (6)tured AAA in 2% (10/608) (missing data n=3). AneurX (Medtronic) 128 (21)
Bard device (Bard, UK) 5 (1)Overall 22% (131/603; missing data n=8) of cases
Excluder (Gore) 1 (<1)were considered “unfit”. In the AT/BI group 15% (57/
Gianturco-Dacron (“Home made”) 107 (17)387) were unfit compared to 34% (74/216) for the Gianturco-PTFE (“Home made”) 14 (2)
Ivanchev-Malmo (“Home made”) 2 (<1)AUIC group. Throughout the results are presented so
Palmaz/PTFE (“Home made”) 65 (11)as to represent the odds of an outcome in the second
Talent (Medtronic) 60 (10)stated group, so the odds of being “unfit” when com- Vanguard (Boston Scientific) 162 (27)
Zenith (Perth) (Cook, U.K.) 26 (4)paring the AT/BI group and the AUIC group are 3.0
Missing 5 (<1)(OR 3.0 (95% CI: 2.0–4.5) p<0.001).
Total 611 (100)Of the 472 fit patients, 36 (8%) were considered “fit”
but “unsuitable” for conventional open repair.
Sixteen/330 (5%) of the fit patients in the AT/BI of unfit patients and 4% (17/472) of fit patients (OR
0.3 (95% CI: 0.1–0.6) p<0.001).group were considered unsuitable for conventional
repair compared to 20/142 (14%) of the AUIC group The median length of procedure was 2 h 30 min
(range: 1–9 h) and the median blood loss 400 ml (range:(OR 3.2 (95% CI: 1.6–6.4) p=0.001).
The mean aneurysm diameter was 6.1 cm (range: 50–7000).
Immediate post procedure outcomes for all patients3.6–14; SD: 1.17). A smaller proportion of patients
treated with an AT/BI device had larger aneurysms and by device type are shown in Table 3. Conversion
to open repair (OR) was required in 5% (32/611) of(>6 cm in diameter): 45% (170/380) vs 65% (134/205)
of those treated with an AUIC device (OR 2.3 (95% cases overall. The reasons for conversion to OR are
shown in Table 4. The rate of conversion improved inCI: 1.6–3.3) p<0.001). Patients with larger aneurysms
were more unfit: 14% (38/276) were unfit if the an- the last year of submission to the registry (Fig. 1),
being 9% (13/146) in 1996, 8% (14/183) in 1997 andeurysm was <6 cm in diameter against 27% (81/301)
unfit if the aneurysm was >6 cm in diameter (OR 2.3 2% (5/282) in 1998 (p=0.002).
In-hospital complication (up to 30 days post pro-(95% CI: 1.5–3.5) p<0.001).
Four per cent (26/611) of patients received an aortic cedure) rates are shown in Table 5 for all patients and
by device type. Details of these in-hospital com-tube device, 60% (366/611) an aorto-bi-iliac device and
36% (219/611) an aorto-uni-iliac device and a crossover plications are given in Table 6.
Thirty-day outcome data was available for 96% (588/graft. The type of devices used are shown in Table 2.
General anaesthesia was used alone in 92% (560/ 611) of cases. Details of 30-day outcomes for all cases,
by device type, fitness and AAA size are shown in603) of cases. Three per cent (19/603) of cases had both
general and regional anaesthesia. Regional anaesthesia Tables 7 and 8. Causes of death at 30 days post
procedure are detailed in Table 9. Conversion to ORwas used alone in 5% (31/611) of cases. Fit patients
had general anaesthesia alone in 95% (446/472) of for fit patients carried a mortality of 20% (5/25) and
if an unfit patient required conversion mortality rosecases against 82% (107/131) of unfit patients (OR 0.9
(95% CI: 0.8–0.9) p<0.001). In unfit patients regional to 66% (4/6).
Length of post-procedure hospital stay was es-anaesthesia was used more commonly than in the fit;
regional anaesthesia was used alone in 11% (14/131) tablished from the date of procedure to discharge, the
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Table 3. Immediate outcomes.
Characteristics All AT/BI AUIC OR (95% CI) p value
Aneurysm excluded 465/611 293/392 172/219 1.5 (0.9–2.4) 0.06
(76%) (75%) (79%)
Additional endovascular procedures 71/611 59/392 12/219 0.3 (0.1–0.6) <0.001
(11%) (15%) (6%)
Additional surgical procedures 30/611 21/392 9/219 0.6 (0.2–1.5) 0.2
(5%) (5%) (4%)
Conversion to open repair 32/611 13/392 19/219 2.9 (1.3–6.4) 0.01
(5%) (3%) (9%)
AT/BI: Aortic tube and bi-iliac devices; AUI: aorto-uni-iliac devices.
Aneurysm exclusion: no flow into aneurysm sac angiographically at end of procedure.
median (range) length of stay was 6 (2–>30) days.
Table 4. Reasons for conversion to open repair (immediate con- Patients treated with an AT/BI device had a shorter
versions n=30, elective conversion n=2). post-procedure length of stay, median (range) of 5
(2–>30) days compared to 8 (2–>30) days for thoseReason for conversion to open repair Number
treated with an AUIC device (p=0.001). Unfit patients
Migration of device 9 had a longer post-procedure length of stay with a
Unable to advance or position prosthesis 7 median (range) of 6 (2–30) days vs 5 (2–30) days forRupture during deployment 3
Persistent endoleak 3 fit patients (p=0.42).
Renal artery dissection/occlusion 2
Acute ruptured AAA; continued haemorrhage 2
Hypotensive collapse, converted. No leak Discussion? vasovagal 1
Graft slipped off deployment balloon 1 Methodological issues
Limb incorrect size 1
Device too small, retrieved, elective conversion 1 The RETA registry was established as a means of
Failure of deployment, explanted electively 1 monitoring the early introduction of endovascular re-No reason stated 1
pair of AAAs during its phase of introduction, priorTotal 32 (5%)
to the establishment of a randomised controlled trial
AAA: Abdominal aortic aneurysm. (RCT). Although endovascular treatment is in its in-
fancy, with rapid technological development it was
Fig. 1. Conversion rate by year.
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Table 5. In-hospital complications.
Characteristics All AT/BI AUIC OR (95% CI) p value
All complications 155/611 78/392 77/219 1.8 (1.2–2.7) 0.007
(25%) (20%) (35%)
Technical complications 34/611 14/392 20/219 2.6 (1.2–5.6) 0.015
(6%) (4%) (9%)
Wound complications 46/611 27/392 19/219 1.1 (0.5–2.3) 0.8
(8%) (7%) (9%)
Renal failure 27/611 14/392 13.219 2.1 (0.9–5.2) 0.1
(4%) (4%) (6%)
Other medical complications 78/611 33/392 45/219 2.1 (1.2–3.5) 0.008
(13%) (8%) (20%)
AT/BI: Aortic tube and bi-iliac devices; AUI: aorto-uni-iliac devices.
Table 6. Complications up to 30 days post procedure. interventions is to use randomisation. Registries have
a number of problems that are common to all ob-Complication Number
servational datasets, and specific problems of their
Technical complication n=34 (6%) own. As data submission is voluntary there is a risk
Endoleak 10 of bias in the data submitted to the registry. SinceEmbolisation (Macro or micro) 9
Graft or limb occlusion 6 there was no attempt with the RETA registry to validate
Stent stenosis/kink 4 the number of cases submitted by each centre, it is not
Enteric fistula-tunnel for crossover 1 possible to ascertain the amount and characteristics ofLimb too short 1
Renal infarction on CT 1 data not submitted. In making comparisons between
Both CIAs covered, buttock claudication 1 groups of patients known confounders can be allowed
Not stated 2 for in analysis. There was only limited data collected on
Wound complication n=46 (8%)
perceived risk factors, but adjustments were necessaryHaematoma/haemorrhage/pseudoaneurysm 22
Infection 16 because of the differences in these factors between
Access artery thrombosis 4 patient groups. However, in comparing groups of
Seroma or lymph leak 3
patients caution is necessary because of unknownFemoral nerve weakness 1
confounding factors, which may be significant. TheRenal failure n=27 (4%)
Other medical complication n=78 (13%) results presented represent the best estimates within
Cardiovascular: MI/arrhythmia/LVF 23 the limitations of the data collected. If these problems
Respiratory: PE/infection 14 are borne in mind then registry data can provideCerebrovascular accident/confusion 9
Fever/PUO: no cause found 9 insight into the results of new treatments, and can be
Ileus 5 useful in planning trials, identifying future data to be
Urinary problems 5 collected and generating hypotheses to be tested.MSOF 3
DVT 2
Other 8
CT: Computed tomography; CIA: common iliac artery; MI: myo-
cardial infarction; LVF: left ventricular failure; PE: pulmonary em- Findings
bolism; PUO: pyrexia of unknown origin; MSOF: multisystem organ
failure; DVT: deep vein thrombosis.
All cases
The registry results confirm the feasibility of endo-
vascular repair and give an insight into likely com-
plication and 30-day outcome rates. Conversion tofelt important that this treatment should be properly
evaluated so that inappropriate claims are not made open repair occurred in 5% of cases, and when needed
the mortality was high (29%). Though “minimallyfor the new “minimally invasive” treatment.9 As a first
step the use of a registry can be of value in assessing invasive”, a 25% all complication rate in the immediate
post procedure period is not insignificant. Two prob-new treatments, but it is important to understand the
limitations of their use.10–12 The only way to eliminate lems that may have been expected appear very un-
common: colonic ischaemia and distal embolisationconfounding and obtain clear results when comparing
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Table 7. Thirty-day outcomes.
Characteristics All AT/BI AUIC OR (95% CI) p Value
Aneurysm excluded 526/588 346/376 180/212 0.9 (0.4–1.4) 0.47
(90%) (92%) (85%)
Persistent endoleaks 34/588 22/376 13/212 0.6 (0.3–1.3) 0.21
(6%) (6%) (6%)
Mortality – all cases 39/588 13/376 26/212 2.6 (1.2–5.9) 0.018
(7%) (4%) (12%)
Mortality – fit patients 16/455 4/314 12/137 8.3 (2.2–31) 0.002
(4%) (1%) (9%)
Mortality – unfit patients 23/126 9/54 14/72 0.9 (0.3–2.5) 0.79
(18%) (16%) (19%)
AT/B: Aortic tube and bi-iliac devices; AUI: aorto-uni-iliac devices.
Aneurysm exclusion: no evidence of endoleak on CT scan at 30 days.
Table 8. Thirty-day outcome by AAA size.
Characteristics All AAA AAA OR (95% CI) p Value
<6 cm >6 cm
Aneurysm excluded 526/588 260/269 244/294 0.2 (0.09–0.4) <0.001
(90%) (97%) (83%)
Persistent endoleaks 34/588 6/269 29/294 5.6 (2.1–14.9) 0.0006
(6%) (2%) (10%)
Mortality 39/588 4/269 31/294 4.4 (1.4–13) 0.009
(7%) (2%) (11%)
AAA: Abdominal aortic aneurysm.
Table 9. Causes of death at 30 days post procedure. the RETA registry on AT/BI devices are very similar
to those reported by EUROSTAR (4% vs 3.2%). ThisCause of death Number
similarity in results for AT/BI cases is probably to be
Cardiovascular: MI, LVF 18 expected, as at least some cases submitted to RETA
MSOF 7 were probably also submitted to the EUROSTAR re-Cerebrovascular: CVA, SAH 5
Haemorrhage during procedure: AAA or IA rupture 3 gistry. The RETA data is more heterogenous, reflecting
Sepsis 2 a wider group of patients treated and devices used
Metastatic lung tumour 1 throughout the United Kingdom. Even so, these resultsPulmonary embolism 1
Small bowel perforation 1 are probably comparable to conventional surgery, par-
Not stated 1 ticularly if only fit patients are considered.4,15,16
Total 39 (6.6%)
MSOF: Multisystem organ failure; CVA: cerebrovascular accident;
SAH: subarachnoid haemorrhage; MI: myocardial infarction; LVF:
Unfit patientsleft ventricular failure; AAA: abdominal aortic aneurysm; IA: iliac
artery.
Because endovascular treatment is considered min-
imally invasive, its use in unfit patients in whom aoccurred infrequently, though distal limb embolisation
did lead to amputation in one case. The majority conventional operation is deemed high risk is ap-
pealing. However, offering this treatment, which isof aneurysms were successfully excluded, though it
seems that this is more difficult to achieve with larger still unproven long-term and which we have shown
has a high complication and mortality in this group,aneurysms. This may be related to a tendency to use
current device sizes in AAA necks and iliac arteries raises important ethical and consent implications.
Clinicians and patients need to consider the trade-that were too large. The data to support this theory is
not available in the registry. The overall mortality was off of expected life expectancy gain from treating an
aneurysm against the morbidity and mortality of thereasonably low at 7%, which is comparable to other
reported series,3–5,13 but higher than the overall mor- procedure itself. The potential long-term benefit in a
group of patients whose principal cause of death maytality recently reported by the EUROSTAR col-
laborators on a European registry.14 However, the not be aneurysm rupture remains to be investigated.
Also, conversion to OR is occasionally required forEUROSTAR registry data does not contain the results
of using AUIC devices, and the mortality rates from these unfit patients, because of complications during
Eur J Vasc Endovasc Surg Vol 21, January 2001
Endovascular Treatment of AAA 63
the procedure, and in an unfit patient the mortality year of data submission and a drop in the rate of
conversion to open repair. These results can probablyrate then became very high (66%).
be attributed to a number of factors: the effect of the
learning curve; better case selection; and im-
Fit patients unsuitable for open repair provements in device design.
Patients with AAA in whom an open repair is relatively
contraindicated because of problems such as a hostile
Length of stayabdomen, inflammatory aneurysm, horseshoe kidney
or gross obesity, but who are otherwise fit, are a
There are potential early cost savings if the lengthparticular group that are well suited to endovascular
of hospital stay is reduced and if those treated byrepair. They have a good life expectancy if the AAA
endovascular repair do not require intensive care. Thisis successfully treated long-term. The registry shows
must be balanced against the cost of the device andthat the 30-day mortality rate at 7% for endovascular
other equipment necessary, and potential cost of treat-repair is comparable to conventional surgery in fit
ing long-term problems, particularly if the device fails.patients suitable for open repair. However, important
The difference in postoperative length of stay betweenquestions are raised in this group of patients about
patients treated by AT/BI and AUIC devices is prob-future endovascular device problems, as later surgical
ably related to local protocols in the units implantingcorrection will remain contraindicated in the majority
AUIC devices, and a requirement to recover from theof patients.
more surgical procedure, the crossover graft in the
AUIC group.
Device types
The AUIC devices can be used to treat a larger pro-
Conclusionportion of aneurysms and we have shown that those
treated with it tend to be older, more unfit and to have
The results for short-term outcomes of endovascularlarger aneurysms. Comparisons with the AT/BI group
AAA repair are encouraging and are similar in termsare difficult because of these differences, which con-
of morbidity and mortality to conventional surgery.found direct comparison of the two groups. Con-
Direct comparison between devices and against con-versions to open repair and technical complications
ventional surgery should ideally be made within awere more frequent with this device and after ad-
randomised trial to avoid confounding influences in-justment the morbidity and mortality rate appeared
herent in observational data, such as that collected byhigher for those treated with AUIC devices, though
registries. Using endovascular repair as an alternativethese findings requires confirmation within a ran-
to conventional repair in high-risk unfit patientsdomised trial.
should be considered carefully in the light of the
burden of co-morbid disease and of the likely rate of
Larger aneurysms death and complications in this group, particularly if
conversion is required.
Larger aneurysms have worse outcomes, with fewer
large aneurysms excluded and a higher mortality
(Table 7). This is important particularly for unfit
Key Messagespatients, who tend to have larger aneurysms. Though
often more technically demanding, there was no in-
• Endovascular repair of AAA is technically feasible,crease in the rate of technical complications in larger
with improved results after the first year.aneurysms, but a trend towards an increase in the
• The mortality for endovascular repair is similarneed for conversion to open repair.
to reported rates for conventional surgery in fit
patients.
• Unfit patients offered treatment in this way had aAssessment of introduction of technique
high death and complication rate.
• A randomised trial with long-term follow-up willThere was evidence of improving results over time,
with a fall in mortality between the first and second be required to compare endovascular repair with
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